Skip to content
Men Under Microscope – Lifestyle
Home
Sample Page
Author:
NanoViricides
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
July 13, 2026
Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
July 8, 2026
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
July 6, 2026
US FDA Has Granted A “Rare Pediatric Disease Drug” Designation for NV-387 As A Treatment for Measles – Enables Priority Review Voucher
June 29, 2026
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
June 22, 2026
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
June 15, 2026
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment – with Superior Oral Administration and Escape Resistance Features Over Antibodies
June 8, 2026
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment – with Superior Oral Administration and Escape Resistance Features Over Antibodies
June 8, 2026
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
May 26, 2026
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
May 19, 2026
1
2
Next Page
→